



Call for Grant Applications CFG-HCV-2024 AbbVie Independent Education (IE)

Therapeutic Area/Disease State	Virology/HCV
Focus	HCV screening and linkage to care
Issue Date:	August 5, 2024
Due Date/CFG Close Date:	September 9, 2024

Background

AbbVie is committed to supporting independent, high-quality, evidence-based education with the most up-to-date information on current, new, and emerging therapies. This helps to expand knowledge, competence, and performance to improve quality of care for patients and support the elimination of health care disparities in underserved patient populations.

Eligibility Criteria

Grant applicants must be US-based and registered in AbbVie’s Grant Management System at grants.abbvie.com with no outstanding reconciliations.

Transparency

AbbVie and the AbbVie grant review and approval process comply with applicable laws, regulations, recommendations and guidance, including, without limitation: guidance from the Department of Health & Human Services Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), “National Physician Payment Transparency Program: OPEN PAYMENTS” (commonly known as the “Sunshine Act”), and internal AbbVie policies and procedures.

AbbVie, at its sole discretion, may disclose the details of funded independent medical education activities, including as may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.



Terms and Conditions

AbbVie reserves the right to approve or deny any or all grant applications received as a result of this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not responsible for any costs associated with this CFG submission.

Submission Directions

1. Please go to grants.abbvie.com and sign in. First-time users should click “Register”
2. In the grant application:
 - STEP 1. Select “Submit New Request” to start the submission process.
 - STEP 2. Select the “Education Requests” button to continue the submission process.
 - STEP 3. Read the Request Submission Instructions and click “Proceed” to enter the request form.
 - STEP 4. Enter Request Information on the General Information Tab.
 - Under Therapeutic Area, select Virology
 - In the Activity Sub-Type field, select Screening & Health Fairs (NOTE: Only Screening & Health Fair CFG submissions will be reviewed, all other submissions will be declined)
 - In the Program Title field, start the title of the grant request as: CFG-HCV-2024
 - STEP 5. Continue entering requested information as outlined in the grant application, including document uploads.
3. If you have questions or require assistance, please contact:

AbbVie Independent Education Department at 877/228-7177 or via email at abbviegrants@abbvie.com.

IMPORTANT: Grant applications submitted in response to this Call for Grants after the due date will not be reviewed by the AbbVie Independent Education Department and will be automatically declined. In addition, grant applications must include the required information outlined in the Submission Directions. Failure to provide this information may result in the grant application being declined.

Decision Date and Notification

Once AbbVie has reached a decision about the grant application, a system-generated email notification will be sent. If the request is approved, the Authorized Signer identified in the grant application must log into the AbbVie grant management system to review and approve the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties prior



Patient Access & Independent Education

CLOSING HEALTHCARE GAPS THROUGH ASSISTANCE, EDUCATION, AND DONATION

to the activity start date. Please do not consider any request approved until an email notification is received from AbbVie stating that the grant request is approved.

Call for Grant Details

Therapeutic Area/Disease state	Virology/HCV
Target Audience	Hepatologists, NPs/PAs involved in HCV care, PCP's, Gastroenterologists, addiction specialists, advocacy partners supporting screening and linkage to care
Geographic Scope	United States
Submission Deadline	September 9, 2024
Anticipated Notification	October/ November 2024
Budget	\$355,000.00 (multiple awards will be considered)

Statement of Need:

The World Health Organization (WHO) has set a global goal of eliminating viral hepatitis B and C by 2030. An estimated 58 million people have chronic hepatitis C virus (HCV) infection with an additional 1.5 million new infections occurring annually (1). Early HCV identification and treatment utilizing simplified approaches, such as those put forward by the American Association for the Study of Liver Disease and the Infectious Disease Society of America (2), are critical in helping reach epidemiologic goals and providing clinical and economic value throughout healthcare systems. In March 2020, the Centers for Disease Control and Prevention and the United States Preventive Services Task Force updated guidance to include universal screening for HCV for adults (3,4). Diagnosis and treatment are no longer relegated to HCV specialists' care: primary care, addiction medicine, women's health, and other healthcare areas are creatively working to meet the 2030 elimination challenge.

We are seeking models of care which include an educational and screening component that reach across underserved populations (including people who use drugs, immigrants, people who are incarcerated, people with mental health challenges, etc.). These models bring education to a broad range of emerging treaters with a focus on addiction specialists, Advanced Practice Providers, Primary Care Physicians, public health groups and patient advocacy groups with the addition of HCV screening directly to the patient using community, street or mobile medicine, including linkage to an HCV care provider. Requests for screening only will not be considered.

References

1. World Health Organization, Hepatitis Elimination. Published 2016. Accessed June 26, 2023 from https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030#tab=tab_1.
2. AASLD/IDSA Simplified Guidelines, published 2022. Accessed June 26, 2023 from <http://hcvguidelines.org>
3. Centers for Disease Control and Prevention. Published 2020. Accessed June 26, 2023 from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm#:~:text=USPSTF%20Recommendations&text=The%20USPSTF%20recommends%20screening%20for,Grade%3A%20B%20Recommendation.>
4. United States Preventive Services Task Force. Published 2020. Accessed June 26, 2023 from <https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/hepatitis-c-screening>